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Abstract
Background: Viral reservoir size refers to cellular human immunodeficiency virus-1 (HIV-1) DNA levels in CD4
+ T
lymphocytes of peripheral blood obtained from patients with plasma HIV-1-RNA levels (viral load, VL) maintained
below the detection limit by antiretroviral therapy (ART). We measured HIV-1 DNA levels in CD4
+ lymphocytes in
such patients to investigate their clinical significance.
Methods: CD4
+ T lymphocytes were isolated from the peripheral blood of 61 patients with a VL maintained at less
than 50 copies/ml for at least 4 months by ART and total DNA was purified. HIV-1 DNA was quantified by nested
PCR to calculate the copy number per 1 million CD4
+ lymphocytes (relative amount) and the copy number in 1 ml
of blood (absolute amount). For statistical analysis, the Spearman rank or Wilcoxon signed-rank test was used, with
a significance level of 5%.
Results: CD4 cell counts at the time of sampling negatively correlated with the relative amount of HIV-1 DNA
(median = 33 copies/million CD4
+ lymphocytes; interquartile range [IQR] = 7-123 copies/million CD4
+
lymphocytes), but were not correlated with the absolute amounts (median = 17 copies/ml; IQR = 5-67 copies/ml).
Both absolute and relative amounts of HIV-1 DNA were significantly lower in six patients in whom ART was
initiated before positive seroconversion than in 55 patients in whom ART was initiated in the chronic phase, as
shown by Western blotting. CD4 cell counts before ART introduction were also negatively correlated with both the
relative and absolute amounts of HIV-1 DNA. Only the relative amounts of HIV-1 DNA negatively correlated with
the duration of VL maintenance below the detection limit, while the absolute amounts were not significantly
correlated with this period.
Conclusions: The amounts of cellular HIV-1 DNA in patients with VLs maintained below the detection limit by the
introduction of ART correlated with the timing of ART initiation but not with the duration of ART. In addition, CD4
+
T lymphocytes, which were newly generated by ART, diluted latently infected cells, indicating that measurements
of the relative amounts of cellular HIV-1 DNA might be underestimated.
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Anti-human immunodeficiency virus (HIV) drugs can
suppress viral replication but cannot directly eliminate
latently HIV-1-infected cells. Replication-competent
HIV-1 can persist in a stable latent reservoir in CD4
+ T
lymphocytes and monocytes, thus carrying integrated
HIV-1 DNA. Among these cells, resting memory CD4
+
T lymphocytes constitute a major latent reservoir [1].
Siliciano et al. calculated the number of latently infected
cells as the frequency of replication-competent virus per
1 million CD4
+ lymphocytes in peripheral blood and
reported that their half-life was about 44 months [2].
The number of latently infected cells in an HIV-1-
infected patient’s body is estimated to be approximately
1 million [3]. The report concluded that an HIV-
infected patient’s body undergoing anti-HIV therapy
(ART) would take 73.4 years for complete viral elimina-
tion; thus, ART would need to be continued for the rest
of the patient’s life [4]. However, the method for calcu-
lating the frequency of replication-competent virus in
this previous report is not necessarily sensitive enough.
An alternative method for estimating the viral reservoir
size of a patient receiving ART is to quantify cellular
HIV-1 DNA in infected cells.
Many studies have reported the amount of cellular
HIV-1 DNA in peripheral blood. In particular, the
recent use of real-time PCR has allowed the straightfor-
ward and accurate measurement of HIV-1 DNA. It also
enables us to distinguish all forms of intracellular HIV-1
DNA, including integrated and unintegrated linear
DNA, as well as 1-long terminal repeat (LTR) and
2-LTR circles. The total HIV-1 DNA in peripheral
blood mononuclear cells (PBMC) and in CD4
+ lympho-
cytes after prolonged viral suppression largely corre-
sponds to integrated HIV-1 DNA [5,6]. This evidence
indicates that integrated HIV-1 DNA is the most stable
form in patients receiving ART, and that viral reservoir
sizes can therefore be estimated by examining the
amounts of cellular HIV-1 DNA.
We reported the detection limit of real-time PCR,
using the LightCycler system, to be 500 copies per 1
million cells in peripheral blood; therefore, HIV-1 DNA
in 30% of the patients receiving ART could not be
quantified using the conventional real-time PCR method
[7]. In a subsequent study, we improved the detection
level of HIV-1 DNA levels with real-time PCR by
including a pre-amplification step in the first PCR, fol-
lowed by quantification with a second PCR [8]. Specifi-
cally, we PCR-amplified the b2-microglobulin (b2M )
gene and HIV-1 DNA simultaneously in the same tube,
quantified the products by TaqMan PCR, and then
determined the amounts of HIV-1 DNA using the copy
number of amplified HIV-1 DNA and the amplification
efficiency of b2 M. This method improved the detection
limit to 2 copies/10
6 cells. Here, we measured the
amount of HIV-1 DNA in CD4
+ lymphocytes in the
peripheral blood using this novel, highly sensitive
method in HIV patients who have undergone ART for a
prolonged period, and in whom the plasma HIV-1 RNA
levels (viral load, VL) remained undetectable.
Methods
Patients and study design
Adult patients visiting either the Osaka National Hospi-
tal or the Kyushu Medical Center and whose VL levels
remained below the detection limit (50 copies/ml) for 4
months or longer were included in this cross-sectional
analysis of an open-labeled cohort of HIV-1-infected
patients successfully treated with ART. Written
informed consent for collection of peripheral blood was
obtained from 69 patients. Of these patients, 8 patients
with a history of rebound of VLs (>400 copies/ml) were
excluded from the study. This study was reviewed and
approved by the institutional review boards of the
Osaka National Hospital and relevant institutions.
Estimation of the number of CD4+ T lymphocytes
(CD4 cell count) and HIV-1 VL
CD4 cell counts were measured by flow cytometry using
the whole-blood lysis method. VLs were measured using
the reverse transcription PCR method (AMPLICOR
HIV-1 monitor test, Roche Molecular Diagnostic), with
a detection limit of 50 copies/ml, according to the man-
ufacturer’s instructions. Serum anti-HIV-1 antibody
levels were detected using LAV Blot I (Bio-Rad Labora-
tories). Sera were determined to be positive for the anti-
body according to the criteria of the World Health
Organization.
Isolation of CD4-positive T lymphocytes and DNA
extraction
Peripheral blood was collected with an EDTA blood col-
lecting tube. CD4-positive T lymphocytes were isolated
from whole blood using StemSep column chromatogra-
phy (Stem Cell Technologies). The collected cells were
then washed with phosphate-buffered saline and resus-
pended. The purity of CD4-positive T lymphocytes was
more than 98% by flow cytometry. For DNA extraction,
1-5 × 10
6 cells were used. DNA was extracted using the
QIAamp DNA Blood Mini Kit (QIAGEN) according to
the manufacturer’s instructions.
Quantification of HIV-1 DNA
HIV-1 DNA was quantified by real-time PCR as pre-
viously reported [8]. A second round of PCR was con-
ducted using the extracted DNA as a template. First, the
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Page 2 of 9human b2 M gene and HIV-1 DNA (Gag) were simulta-
neously amplified in the same tubes used for pre-quanti-
fication PCR. The first round of PCR consisted of 20
cycles of amplification. Subsequently, TaqMan PCR was
used to determine the copy numbers of the pre-ampli-
fied human b2Mg e n ea n dH I V - 1D N A .T h ec o p y
number of HIV-1 DNA was calculated as the copy num-
ber per 10
6 cells (relative amount) using the amplifica-
tion efficiency of human b2 M. The copy number of
HIV-1 DNA contained in CD4
+ T lymphocytes in 1 ml
of blood was determined as an absolute amount. The
absolute amount of HIV-1 DNA was calculated using
the following formula:
Absolute amount (copies/ml) = Relative amount (copies/106 CD4+ lymphocytes)×CD4 cell count (/µl)/1000.
Statistical analysis
For statistical analysis, the Wilcoxon signed-rank test
was used for intergroup comparisons and the Spearman
rank test was used for correlation analysis. All analyses
were conducted with a significance level of 5%.
Results
The general characteristics of the 61 patients included in
the study are presented in Table 1. CD4
+ lymphocytes
were isolated from peripheral blood, and HIV-1 DNA
contained in these isolated cells was quantified using the
method described above. The distributions of values for
relative and absolute amounts of HIV-1 DNA in CD4
+
lymphocytes are shown in Figure 1. The absolute
amounts were generally lower than the relative ones.
However, both relative and absolute amounts exhibited
a similar distribution. Seven patients (11%) had values
below the detection limit (2 copies/10
6 CD4
+ lympho-
cytes) when relative amounts were assessed, whereas 10
patients (16%) had values below the detection limit (2
copies/ml) when absolute amounts were assessed.
The correlation between the amounts of HIV-1 DNA
and CD4 cell counts at the time of sampling was exam-
ined using Spearman’s rank test (Figure 2). A significant
negative correlation was noted between the relative
amounts of HIV-1 DNA and CD4 cell counts (Spear-
man’s r = -0.3164, p = 0.013). This indicates that the
latently infected cells may be diluted with newly gener-
ated T lymphocytes after the introduction of ART.
Table 1 Demographic and clinical characteristics of HIV-1-infected patients
Characteristic Absolute value
Number of participants 61
Number of male participants, (%) 56 (92%)
Age (y), median [IQR] 43 [35-48]
Route of transmission, (%)
homosexual 46 (76%)
heterosexual 13 (21%)
blood products 2 (3%)
Nationality, (%)
Japanese 61 (100%)
Nadir CD4 cell count (/μl), median [IQR]* 175 [54-256]
Pre-ART VL (copies/ml), median [IQR]* 85500 [41500-322500]
Current CD4 cell count (/μl), median [IQR] 569 [442-818]
Current ART regimen, no. (%)
PI-based 32 (52%)
NNRTI-based 25 (41%)
3-NRTI 4 (7%)
Duration of VL suppression (days), median [IQR] 2205 [784-2737]
* Data are unavailable for seven (11%) patients. IQR, interquartile range; VL, viral load; ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, non-nucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
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Figure 1 Relative and absolute HIV-1 DNA levels in all patients.
The dots indicate the amounts of intracellular HIV-1 DNA per 10
6
CD4
+ lymphocytes (relative amount, left) and the amounts of HIV-1
DNA per 1 ml of blood (absolute amount, right). The dotted line
indicates the detection limit for HIV-1 DNA.
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Page 3 of 9However, there was no significant correlation between
the absolute amounts of HIV-1 DNA calculated as copy
numbers in 1 ml of blood and CD4 cell counts at this
time point (Figure 2B).
The patients were divided into 2 groups depending on
when ART was introduced: 6 patients in whom ART
was introduced before positive seroconversion, as shown
by Western blotting (before-SC group), and 55 patients
in whom ART was introduced in the chronic phase
(chronic group). The two groups were compared to
determine the association between the amounts of HIV-
1 DNA and the timing of ART introduction (Figure 3).
In the before-SC group, for which therapy was initiated
before seroconversion, HIV-1 DNA was not detected in
half of the patients (three patients) (i.e., below the detec-
tion limit of 2 copies/10
6 CD4
+ lymphocytes). In the
chronic group, HIV-1 DNA was not detected in 4 of 55
patients (7%). Comparison of the amounts of HIV-1
DNA between these two groups demonstrated that the
relative and absolute amounts were lower in the before-
S Cg r o u pt h a ni nt h ec h r o n i cg r o u p( p=0 . 0 1 6a n dp=
0.0027, respectively). Subsequently, we examined the
correlation between the CD4 cell counts immediately
before the initiation of ART (nadir CD4 cell counts) and
the amounts of HIV-1 DNA. We analyzed nadir CD4
cell counts in 48 patients in whom ART was initiated
in the chronic phase; nadir CD4 cell counts in 7 patients
were unavailable at the time of the study. As shown in
Figure 4, both the relative and absolute amounts nega-
tively correlated with nadir CD4 cell counts. No signifi-
cant correlation was noted between the amounts
of HIV-1 DNA and the VLs immediately before the
introduction of ART (relative: Spearman’s r = 0.2192,
p = 0.1344; absolute: Spearman’s r = 0.2471, p =
0.0904). Collectively, these observations indicate that the
amounts of cellular HIV-1 DNA in HIV-1-infected
patients during ART correlated with the time when
therapy was initiated. Moreover, the amounts of cellular
HIV-1 DNA were maintained at lower levels, particu-
larly in patients in whom ART was initiated earlier after
HIV-1 infection.
We next investigated the association between the
amount of HIV-1 DNA and the current ART regimen.
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Figure 2 Correlation between HIV-1 DNA levels and CD4 cell
counts at the time of sampling. (A) Negative correlation between
the relative amounts and CD4 cell counts at the time of sampling.
Spearman’s rank test was used for statistical analysis. Spearman’s
correlation coefficients (r) and p-values are indicated in the figure.
The straight line (y = 2.12 - 0.00103x, p = 0.01) was calculated using
linear regression analysis. Samples below the detection limit were
assumed to be 1 copy in the calculation. (B) There was no
correlation between the absolute amounts and CD4 cell counts at
the time of sampling. Spearman’s rank test and linear regression
analysis (y = 1.47 - 0.000368x, p = 0.3342) were used for statistical
analysis.
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Figure 3 HIV-1 DNA levels in patients in whom the therapy
was introduced before seroconversion. The relative (left) and
absolute amounts (right) of HIV-1 DNA in patients in whom therapy
was initiated during the chronic phase (chronic) or before
seroconversion (before SC). The Wilcoxon test was used for
statistical analysis.
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Page 4 of 9The 61 patients were divided into 3 groups according to
the antiretroviral drugs they received: protease inhibitor-
based regimen (PI group, n = 32), non-nucleoside
reverse transcriptase inhibitor-based regimen (NNRTI
group, n = 25), and 3-nucleoside reverse transcriptase
inhibitor regimen (3NRTI group, n = 4). Amongst the
three groups, the HIV-1 DNA levels were highest in the
3NRTI group. However, no significant differences were
observed in either the relative or absolute amounts of
HIV-1 DNA among the three groups (Wilcoxon signed-
rank test, relative: p = 0.3325, absolute: p = 0.4091).
Median HIV-1 DNA levels in the PI group (relative: 50
copies/10
6 CD4
+ lymphocytes; absolute: 25 copies/ml)
were similar to those in the NNRTI group (relative: 23
copies/10
6 CD4
+ lymphocytes; absolute: 17 copies/ml).
Finally, the amounts of HIV-1 DNA and the duration
of ART were examined. The duration of ART was
defined as the period during which VL was maintained
below the detection limit. The relative amounts of HIV-
1 DNA showed a significant negative correlation with
the duration of undetectable VLs (Figure 5A). A regres-
sion analysis, conducted based on the assumption that
the amounts of HIV-1 DNA in patients with their VLs
below the detection limit were 1 copy/10
6 CD4
+ lym-
phocytes, provided a straight line, as shown in Figure
5A (p = 0.0459). The half-life of HIV-1 DNA calculated
from the regression line was about 1,400 days (47
months). As shown in Figure 5B, there was no correla-
tion between the absolute amounts of HIV-1 DNA and
the duration of undetectableV L s .I na d d i t i o n ,t h eh a l f -
life of HIV-1 DNA was extended to about 2,300 days
(78 months; p = 0.215). The duration of ART and the
CD4 cell counts at the time of sampling were moder-
ately correlated (data not shown, Spearman’s r = 0.400,
p = 0.001), suggesting that the CD4 cell counts increased
as the duration of ART increased.
Discussion
In this study, the amounts of cellular HIV-1 DNA in
peripheral CD4
+ lymphocytes were measured in patients
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Figure 4 Correlation between HIV-1 DNA levels and CD4 cell
counts before ART introduction. (A) Relative amounts (best-fit
line: y = 2.23 - 0.00321x, p = 0.0005) and (B) absolute amounts
(best-fit line: y = 1.83 - 0.00237x, p = 0.0085) of HIV-1 DNA levels.
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Figure 5 Correlation between the amounts of HIV-1 DNA and
the period with undetectable VL. (A) Relative amounts (best-fit
line: y = 2.02 - 0.000216x, p = 0.0459), and (B) absolute amounts
(best-fit line: y = 1.60 - 0.000128x, p = 0.2147) of HIV-1 DNA levels.
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Page 5 of 9with VLs continuously maintained by ART below the
detection limit using a novel, highly sensitive method
[8]. Collectively, the data presented here indicate that
while the viral replication was favorably suppressed with
anti-HIV drugs for a prolonged period, HIV-1 DNA can
be quantified in about 90% of these patients. This is
similar to the detection limits previously reported [9,10].
In addition to the nested PCR methods, quantifying
HIV-1 DNA in isolated CD4
+ lymphocytes contributed
to improved sensitivity of the assay because these cells
are the major reservoir of PBMC, and their use
increases the population containing HIV-1 DNA [1].
However, purification of CD4
+ lymphocytes eliminates
minor viral reservoir cells, such as monocytes, from the
analysis. The amounts of HIV-1 DNA in monocytes in
patients with HIV-1-associated dementia are higher than
those in HIV-1-infected patients without dementia
[11,12]. Furthermore, ultra-deep pyrosequencing has
shown that there is high HIV-1 heterogeneity in mono-
cytes compared with CD4
+ lymphocytes, suggesting a
possible source of viral diversity [13]. Whilst these
observations highlight the importance of examining
monocyte reservoirs, we used only the CD4+ lympho-
cyte population rather than PBMC to improve the sensi-
tivity of cellular HIV-1 DNA detection in this study.
The amount of cellular HIV-1 DNA in CD4
+ lympho-
cytes is generally calculated as the copy number per 1
million CD4
+ lymphocytes or per 1 μgo ft o t a lD N A .I n
this study, the values calculated using this method were
defined as the relative amounts. As reported previously,
a negative correlation was noted between the relative
amounts of HIV-1 DNA and CD4 cell counts at the
time of sampling [6,14], and the duration of therapy
[15-18]. These results indicate that HIV-1-uninfected
CD4
+ lymphocytes may be newly generated during
ART, which could dilute the amounts of latently
infected cells. Thus, an examination of the relative
amounts may result in an underestimation of the
amounts of HIV-1 DNA, and may not correctly reflect
the viral reservoir of an HIV-1-infected patient’sb o d y .
The relative amounts were corrected for the CD4 cell
counts at the time of sampling, and were also analyzed
as copy number in CD4
+ lymphocytes in 1 ml of blood
(absolute amounts). After this correction, there was no
negative correlation between the amounts of HIV-1
DNA and CD4 cell counts at the time of sampling.
Thus, it seemed appropriate to examine absolute
amounts as well as relative amounts of HIV-1 DNA in
CD4
+ lymphocytes to determine the effect of ART on
viral reservoir size.
A negative correlation between the relative amounts of
HIV-1 DNA and the duration of ART was noted in this
study. A regression analysis demonstrated that the
amounts of cellular HIV-1 DNA were halved when VLs
were suppressed below the detection limit for about 47
months. This half-life was almost equivalent to that of
latently infected cells previously reported by Siliciano et
al. (about 44 months) [2]. In this previous report, the
half-life was calculated by counting latently infected
cells per 1 million CD4
+ lymphocytes for 7 years, and
the researchers concluded that it took 73.4 years to
eliminate all latently infected cells. However, the possi-
ble dilution of latently infected cells with newly gener-
ated CD4
+ lymphocytes was not addressed. As indicated
in this study, there was no correlation between the abso-
lute amounts and duration of therapy, and the half-life
was extended to about 78 months. Although the accu-
racy of the half-life calculated here is limited by the fact
that this study is not a longitudinal study, previous
reports of the time required for ART to eliminate HIV-
1 from patients’ bodies are likely to be underestimates.
In addition to the decline rate of latently infected cells
in the CD4
+ lymphocyte reservoir, the decline rate of
cellular HIV-1 DNA in PBMC has also been investi-
gated. Longitudinal studies involving patients under-
going long-term ART have shown that the amount of
cellular HIV-1 DNA in PBMC decreased by 2.5-3.0
copies/10
6 PBMC in the first year within initiating ART
[16,18,19]; this was followed by a milder decrease and
levels reached a plateau after about 80 weeks [20,21] or
3 years [18]. These results resemble the decline in the
absolute amounts of cellular HIV-1 DNA rather than
the relative amounts seen in the present study, although
the comparison between the amounts of HIV-1 DNA in
PBMC and relative and absolute amounts of HIV-1
DNA in CD4
+ lymphocytes was not performed in this
study.
No differences were observed in the amount of HIV-1
DNA between the PI and NNRTI groups in this study.
In a previous observational study, the amounts of HIV-1
DNA in the PI and NNRTI groups showed no signifi-
cant differences using the Kruskal-Wallis test [22]. How-
ever, in this previous study, subjects with high levels of
HIV-1 DNA were more common in the NNRTI group
than in the PI group, suggesting the possibility that PI
treatment may have a greater impact on viral reservoir
than NNRTI. These two previous studies, however, did
not conclusively address the effects of anti-HIV drugs
on viral reservoir because they were not randomized
controlled studies. Nevertheless, the use of drugs that
exert a beneficial effect on the clearance of HIV-1 DNA
might reduce the half-life of latently infected cells.
Recently, Buzón et al. reported that intensification of
ART treatment with raltegravir, an HIV-1 integrase
inhibitor, in patients on standard ART led to a transient
increase in 2-LTR circles [23]. This suggests that
ongoing viral replication persists despite suppressive
ART, and that raltegravir prevents linear HIV-1 DNA
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of linear DNA to 2-LTR circles. The continual replen-
ishment of viral reservoirs by ongoing viral replication is
thought to be a mechanism responsible for the longevity
of viral reservoir. Further studies are required to deter-
mine whether raltegravir can reduce the half-life of the
viral reservoir by arresting ongoing viral replication that
seems to occur during ART.
In agreement with previous reports [24,25], this study
demonstrates that the amounts of HIV-1 DNA are main-
tained at low levels in patients in whom ART was initiated
before the production of anti-HIV antibody. Previous
reports that examined the impact of 1 year of ART
showed that ART reduces the cellular HIV-1 DNA level
more effectively when initiated during the acute rather
than the chronic phase of HIV-1 infection. Given these
observations, our results indicate that this effect could
continue for a prolonged period because our patients
received long-term ART (median = approximately 6
years). It should be noted that six patients in whom ther-
apy was initiated before seroconversion required the intro-
duction of ART to alleviate the symptoms of acute HIV
infection. Most of these patients had more severe symp-
toms than patients with usual acute HIV infection. Thus,
it is unlikely that the amounts of HIV-1 DNA were main-
tained at low levels by low viral replication. In addition to
these observations, the CD4 cell counts before the intro-
duction of ART were negatively correlated with the
amounts of HIV-1 DNA. Pre-ART VLs also tended to cor-
relate with the amounts of HIV-1 DNA, but without sta-
tistical significance. This suggests that the latently infected
cells might be established early after infection [26,27] and
increase gradually during an asymptomatic period. In sup-
port of this, several studies have followed asymptomatic
carriers with stable VLs for a long time and shown a gra-
dual increase in cellular HIV-1 DNA [28] and an increase
in the amount of HIV-1 DNA together with the progres-
sion of immunodeficiency [29,30].
The amounts of HIV-1 DNA were significantly lower,
in patients in whom ART was introduced before sero-
conversion. Because HIV-1 DNA could not be detected
in three of the six patients of the before-SC group, this
study cannot demonstrate the actual suppression level
of cellular HIV-1 DNA in these patients. Moreover,
these results need to be interpreted carefully in light of
some conflicting results on the amount of HIV-1 DNA
in patients treated with ART during the acute phase
[31,32], and negative results about the potential clinical
usefulness of estimation of the HIV-1 DNA level
[33-36]. The present study is limited by its small cohort
size (especially the before-SC group), and blood samples
were obtained from patients enrolled at two centers,
resulting in a cross-sectional study design. Therefore,
further longitudinal studies are required to confirm our
preliminary findings from a small cohort of patients. In
the future, we hope to develop a more sensitive analysis
method to determine the effects of ART intervention in
t h ea c u t ep h a s eo fH I V - 1i n f e c t i o nb ye x a m i n i n gt h e
relationship between the amounts of cellular HIV-1
DNA and long-term course of ART.
Conclusions
Here, we analyzed samples from 61 patients to examine
the significance of the amounts of HIV-1 DNA. The
amounts of HIV-1 DNA were correlated with the timing
of ART introduction, but not with the duration of ART.
In addition, CD4
+ T lymphocytes, newly generated by
ART, diluted latently infected cells, indicating that
the relative amounts of cellular HIV-1 DNA might be
underestimated. In addition to analysis of the relative
amount, quantifying the absolute amount of cellular
HIV-1 DNA would be helpful in providing an accurate
measure of HIV-1 DNA in CD4
+ T lymphocytes.
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